Edwards Lifesciences’ (NYSE:EW) and cardiovascular artificial intelligence medtech firm Bay Labs, have inked a multi-faceted collaborative cardiovascular-focused development deal, Bay Labs said today.
San Francisco-based Bay Labs said that the partnership involves multiple initiatives including the development of new AI-powered algorithms in Bay Labs’ EchoMD software suite and the integration of EchoMD algorithms into Edwards’ CardioCare quality care navigation platform, as well as support for ongoing clinical studies.
“Our vision is to improve patient care throughout the continuum from disease detection to appropriate intervention. Working with Edwards to deploy Bay Labs’ AI software with deep learning technology into clinical settings has the potential to derive quality improvements and to increase the accuracy of timely heart disease detection,” Bay Labs co-founder & CEO Charles Cadieu said in a prepared statement.
Bay Labs said that it has already integrated EchoMD algorithms into the CardioCare platform for investigational use to “retrospectively analyze echocardiograms,” and added that it believes that integration of the existing and future algorithms could improve quality and increase heart disease detection.
“It is unfortunate that patients suffering from severe aortic stenosis frequently do not receive a proper diagnosis, for a variety of reasons. The value of Bay Labs’ technology is in providing help for these patients to be appropriately diagnosed and successfully find their way to proper treatments,” Edwards strategy & corp dev corporate VP Don Bobo said in prepared remarks.
Earlier this month, Edwards Lifesciences launched a pivotal trial of its Pascal mitral valve repair system, with the first procedure being performed at Atlantic Health System’s Morristown Medical Center.